Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in unresectable hepatocellular carcinoma
NCT01639352Phase 2Completed
- Start
- Jul 2012
- Primary completion
- Aug 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in hepatocellular carcinoma (HCC). Started Jul 2012; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01639352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639352.